Kooperativer Bibliotheksverbund

UID:

Format: xi, 220 Seiten , Illustrationen (farbig), Diagramme (teilweise farbig) , 23 cm

Edition: First edition

ISBN: 9780128119228

Series Statement: Advances in cancer research volume 135

Note: Literaturangaben , Chapter One. MicroRNAs and cancer: a long story for short RNAs -- Chapter Two. The enigma of miRNA regulation in cancer -- Chapter Three. Animal models to study microRNA function -- Chapter Four. Cancer hallmarks and microRNAs: the therapeutic connection -- Chapter Five. microRNAs in cancer susceptibility -- Chapter Six. Role of the tRNA-derived small RNAs in cancer: new potential biomarkers and target to therapy -- Chapter Seven. MicroRNAs and epigenetics

Language: English

Subjects: Medicine

UID:

Format: 1 online resource (434 pages)

ISBN: 9780128232743

Note: Description based on publisher supplied metadata and other sources

Language: English

URL: lizenzpflichtig

UID:

Format: 1 Online-Ressource

ISBN: 9780128232743 , 0128232749

Note: Intro -- MicroRNA in Human Malignancies -- Copyright -- Contents -- Contributors -- Section A: miRNAs involvement in basic mechanisms of cancer development -- Chapter 1 Overview on miRNA classification, biogenesis, and functions -- Introduction -- MicroRNA and the complex biological system of gene expression -- MicroRNA biogenesis, nomenclature, and classification -- Origins of the canonical primary miRNA transcript -- From canonical primary miRNA to mature miRNA -- Noncanonical miRNA biogenesis and isomiRs -- Nomenclature and classification -- Mechanisms of miRNA-mediated gene regulation -- Posttranscriptional regulation of mRNA stability and translation -- Models of miRNA-mediated gene regulation within the nucleus -- The dynamics of miRNA-mediated gene regulation -- MicroRNA abundance and turnover -- Concluding remarks -- References -- Chapter 2 microRNA in cancer: An overview -- The dawn of miRNAs in human biology -- First reported miRNA cancer-associated alterations -- The age of discovery: Microarrays and miRNA cancer signatures -- Functional classification of miRNA: The line between tumor suppressor and oncomiRs -- Development of miRNA as biomarkers -- The transition of miRNA into clinics -- Conclusion and future perspectives -- References -- Chapter 3 miR-15/16 in human malignancies -- 13q deletions in CLL and miR-15/16 -- Other mechanisms of miR-15/16 dysregulation -- Interplay between ROR1, Bcl2, and miR-15/16 in CLL -- miR-15/16 in mice -- miR-15/16 in human AML and MDS -- miR-15/16 in solid cancers -- References -- Chapter 4 microRNAs and tumor suppressor p53 regulation -- p53 and its signaling pathway -- GOF mutant p53 in cancer -- miRNAs regulated by wild-type p53 -- miRNAs that directly regulate p53 -- miRNAs that indirectly regulate p53 -- miRNAs regulated by GOF mutp53 -- Conclusion -- References. , Chapter 5 MicroRNA involvement in invasion and metastasis -- Introduction-The process of metastasis -- Direct regulation of metastasis -- Metastasis-promoting miRNAs -- Metastasis-Suppressing miRNAs -- Indirect regulation of metastasis -- Regulation of miRNA biosynthesis -- RNA-RNA interaction-based miRNA regulation -- Translational application of metastasis-associated miRNAs -- Noninvasive biomarkers -- miRNAs as therapeutics -- Conclusions and perspectives -- Acknowledgment -- References -- Chapter 6 microRNAs and metabolism -- Introduction -- Trafficking and consumption of glucose -- NcRNAs regulate glucose trafficking in cancer cells by altering GLUT levels -- NcRNAs regulate key glycolytic enzymes -- Branched pathways of glycolysis -- NcRNAs can influence glucose metabolism by regulating cancer-associated signaling pathways -- PI3K/Akt/mTOR and HIF-1 signaling pathway -- p53 signaling pathway -- Conclusion and future perspectives -- References -- Chapter 7 microRNAs in inflammation processes -- Introduction -- MiRNA biogenesis and functions -- Inflammation and mechanism of activation -- miRNAs in inflammatory disease -- Chronic respiratory diseases -- Cystic fibrosis (CF) -- Chronic obstructive pulmonary disease (COPD) -- Asthma -- Cardiovascular diseases -- Atherosclerosis -- Myocardial infarction (MI) and ischemia reperfusion injury (MIRI) -- Autoimmune diseases -- Systemic lupus erythematosus (SLE) -- Rheumatoid arthritis (RA) -- Multiple sclerosis (MS) -- Cancer -- Colorectal cancer (CRC) -- Lung cancer (LC) -- Prostate cancer (PC) -- Conclusion -- References -- Section B: miRNAs methodologies -- Chapter 8 Wet-lab methods for miRNA analysis -- Introduction -- Methods for miRNA discovery and detection -- Northern blot -- Hybridization microarrays -- Quantitative PCR -- Next-generation sequencing -- Functional miRNA analysis. , Classical target validation methods: Reporter genes and RISC immunoprecipitation -- High-throughput methods for target identification -- Functional validation -- Final remarks -- Acknowledgments -- References -- Chapter 9 Bioinformatics utilities, web resources and integrative strategies for the analysis of miRNA regulatory networks -- Introduction -- Target prediction algorithms -- Single predictors -- Multiple predictors -- In silico functional assessment of miRNAs: Tips and tricks -- Functional analysis of miRNAs associated with survival time in lung adenocarcinoma: A test case -- Conclusions -- Acknowledgments -- References -- Chapter 10 Computational resources for analysis of miRNA targetome -- Introduction -- miRNA target databases -- miRNA target databases for human -- miRNA target databases for other species -- miRNA algorithms -- miRNA target prediction for humans -- miRNA target prediction for other species -- miRNA target prediction for plants -- Conclusion -- References -- Chapter 11 miRNA bioinformatics and pathway analysis -- The microRNA synergy -- Role of microRNAs in biological signaling pathways -- Pathways: The manually curated maps of the cell interactome -- The miRNA interactome -- miRNA pathway analysis methods -- ORA on miRNA targets -- FCS on miRNA targets -- Topological approaches of pathway analysis with miRNAs -- Computational tools for miRNA pathway analyses -- Conclusions -- Funding -- References -- Section C: miRNAs involvement in therapeutics/theranostics -- Chapter 12 Opportunities of miRNAs in cancer therapeutics -- Introduction -- MicroRNAs in cancer. OncomiRs and tumor-suppressor miRNAs -- Alterations in miRNAs and their appeal for cancer therapy -- MicroRNA-based drug design -- Choosing the therapeutic strategy: miRNA mimics, antagomiRs, and more -- Chemical modifications of RNA-based drugs. , Delivery of RNA-based drugs -- Chemical modifications -- Liposomes, micelles, and exosomes -- Nanoparticles -- Viral vectors -- Bacteria-based vectors (EDV nanocells) -- MicroRNA-based therapeutics in the current clinic -- MRX34 -- Cobomarsen -- TargomiRs -- Remlarsen -- Other preclinical studies -- The future of miRNAs in the clinic -- Current challenges in the use of miRNAs -- Quick degradation in the bloodstream -- Extrahepatic delivery to tumor site -- Limited tissue penetration -- Endocytosis and endosome entrapment -- Off-targets and side effects -- Other challenges -- Future perspectives -- References -- Section D: miRNAs involvement in human cancer: Pathophysiology and translational opportunities -- Chapter 13 Pathophysiology roles and translational opportunities of miRNAs in acute leukemias -- Introduction -- MiRNAs involved in the pathogenesis of AML -- miRNAs as biomarkers -- miRNAs in chemoresistance -- miRNAs as therapeutic targets -- Role of miR-15/16 clusters in AML pathogenesis -- Conclusions -- References -- Chapter 14 Pathophysiology roles and translational opportunities of miRNAs in CLL -- MicroRNAs and the cellular origin of CLL cells -- MicroRNAs and CLL genetics -- microRNAs in proliferation and survival of CLL cells -- microRNAs and BCR signaling -- MicroRNAs and microenvironment -- MicroRNAs and apoptosis -- Translational opportunities -- References -- Chapter 15 Pathophysiology roles and translational opportunities of miRNAs in lymphoma -- Summary -- miRNAs and pathophysiology -- miRNAs regulate the expression of genes that promote B-cell differentiation -- Lymphomagenesis -- DLBCL and miRNA -- MZL and miRNA -- Diagnosis -- Prognosis -- References -- Chapter 16 Pathophysiology roles and translational opportunities of miRNAs in breast cancer -- Breast physiology and pathology -- Breast physiology -- Breast pathology.

Additional Edition: Erscheint auch als 0128222875

Additional Edition: 9780128222874

Language: English

URL: lizenzpflichtig

UID:

Format: 1 Online-Ressource (1972 pages)

Edition: 10th ed

ISBN: 9781119750697

Additional Edition: 9781119750680

Additional Edition: Erscheint auch als Druck-Ausgabe Bast, Robert C., Jr Holland-Frei Cancer Medicine Newark : John Wiley & Sons, Incorporated,c2023 9781119750680

Language: English

URL: lizenzpflichtig

URL: Cover

UID:

Format: 10

ISSN: 1538-7445

Content: Estrogen receptor α (ERα) upregulation causes abnormal cell proliferation in about two thirds of breast cancers, yet understanding of the underlying mechanisms remains incomplete. Here, we show that high expression of the microRNA miR-375 in ERα-positive breast cell lines is a key driver of their proliferation. miR-375 overexpression was caused by loss of epigenetic marks including H3K9me2 and local DNA hypomethylation, dissociation of the transcriptional repressor CTCF from the miR-375 promoter, and interactions of ERα with regulatory regions of miR-375. Inhibiting miR-375 in ERα-positive MCF-7 cells resulted in reduced ERα activation and cell proliferation. A combination of expression profiling from tumor samples and miRNA target prediction identified RASD1 as a potential miR-375 target. Mechanistic investigations revealed that miR-375 regulates RASD1 by targeting the 3′ untranslated region in RASD1 mRNA. Additionally, we found that RASD1 negatively regulates ERα expression. Our findings define a forward feedback pathway in control of ERα expression, highlighting new strategies to treat ERα-positive invasive breast tumors. Cancer Res; 70(22); 9175-84. ©2010 AACR.

Note: Gesehen am 01.08.2023

In: Cancer research, Philadelphia, Pa. : AACR, 1916, 70(2010), 22, Seite 9175-9184, 1538-7445

In: volume:70

In: year:2010

In: number:22

In: pages:9175-9184

In: extent:10

Language: English

DOI: 10.1158/0008-5472.CAN-10-1318

URL: Volltext  (lizenzpflichtig)

UID:

Format: xxix, 1971 Seiten , Diagramme, Illustrationen

Edition: Ninth edition

ISBN: 9781118934692

Content: "The original reference resource for medical oncologists, radiation oncologists, internists, and allied specialties involved in the treatment of cancer patients, Holland-Frei Cancer Medicine covers the ever-expanding field of current cancer science and clinical oncology practice. In this new ninth edition an outstanding editorial team from world-renowned medical centers continue to hone the leading edge forged in previous editions, with timely information on biology, immunology, etiology, epidemiology, prevention, screening, pathology, imaging, and therapy. Holland-Frei Cancer Medicine, Ninth Edition, brings scientific principles to clinical practice and is a testament to the ethos that innovative, comprehensive, multidisciplinary treatment of cancer patients must be grounded in a fundamental understanding of cancer biology. This ninth edition features hundreds of full color illustrations, photographs, tables, graphs and algorithms that enhance understanding of complex topics and make this text an invaluable clinical tool. Over 15 brand new chapters covering the latest advances, including chapters on Cancer Metabolism, Bioinformatics, Biomarker Based Clinical Trial Design, Health Services Research and Survivorship bring this comprehensive resource up-to-date. Each chapter contains overview boxes, select references and other pedagogic features, designed to make the content easy to access and absorb"--Provided by publisher

Note: Includes bibliographical references and index , Preceded by Holland-Frei cancer medicine 8, 2010

Additional Edition: 9781119000846

Additional Edition: 9781119000839

Additional Edition: 9781119000846

Additional Edition: 9781119000839

Additional Edition: Erscheint auch als Online-Ausgabe Holland-Frei cancer medicine Hoboken, New Jersey : John Wiley & Sons, Inc., 2016

Language: English

Keywords: Onkologie

URL: Cover